231 related articles for article (PubMed ID: 38037159)
1. Upregulated PARP1 confers breast cancer resistance to CDK4/6 inhibitors via YB-1 phosphorylation.
Quan C; Wu Z; Xiong J; Li M; Fu Y; Su J; Wang Y; Ning L; Zhang D; Xie N
Exp Hematol Oncol; 2023 Nov; 12(1):100. PubMed ID: 38037159
[TBL] [Abstract][Full Text] [Related]
2. Elacestrant (RAD1901) exhibits anti-tumor activity in multiple ER+ breast cancer models resistant to CDK4/6 inhibitors.
Patel HK; Tao N; Lee KM; Huerta M; Arlt H; Mullarkey T; Troy S; Arteaga CL; Bihani T
Breast Cancer Res; 2019 Dec; 21(1):146. PubMed ID: 31852484
[TBL] [Abstract][Full Text] [Related]
3. Clinical considerations of CDK4/6 inhibitors in HER2 positive breast cancer.
Zhang C; Zhou F; Zou J; Fang Y; Liu Y; Li L; Hou J; Wang G; Wang H; Lai X; Xie L; Jiang J; Yang C; Huang Y; Chen Y; Zhang H; Li Y
Front Oncol; 2023; 13():1322078. PubMed ID: 38293701
[TBL] [Abstract][Full Text] [Related]
4. Practical Treatment Strategies and Future Directions After Progression While Receiving CDK4/6 Inhibition and Endocrine Therapy in Advanced HR
Sammons S; Shastry M; Dent S; Anders C; Hamilton E
Clin Breast Cancer; 2020 Feb; 20(1):1-11. PubMed ID: 31780379
[TBL] [Abstract][Full Text] [Related]
5. Chemotherapy modulates CDK4/6 inhibitors resistance in metastatic breast cancer by Rb1 mutations: a case report and literature review.
Gao L; Shen X; He L; Wu J; Liu Y; Wang X; Shao X
Ann Transl Med; 2022 Jan; 10(2):117. PubMed ID: 35282060
[TBL] [Abstract][Full Text] [Related]
6. Metabolic Adaptations to MEK and CDK4/6 Cotargeting in Uveal Melanoma.
Teh JLF; Purwin TJ; Han A; Chua V; Patel P; Baqai U; Liao C; Bechtel N; Sato T; Davies MA; Aguirre-Ghiso J; Aplin AE
Mol Cancer Ther; 2020 Aug; 19(8):1719-1726. PubMed ID: 32430489
[TBL] [Abstract][Full Text] [Related]
7. CDK4 phosphorylation status and rational use for combining CDK4/6 and BRAF/MEK inhibition in advanced thyroid carcinomas.
Pita JM; Raspé E; Coulonval K; Decaussin-Petrucci M; Tarabichi M; Dom G; Libert F; Craciun L; Andry G; Wicquart L; Leteurtre E; Trésallet C; Marlow LA; Copland JA; Durante C; Maenhaut C; Cavaco BM; Dumont JE; Costante G; Roger PP
Front Endocrinol (Lausanne); 2023; 14():1247542. PubMed ID: 37964967
[TBL] [Abstract][Full Text] [Related]
8. Resistance to cyclin-dependent kinase (CDK) 4/6 inhibitors confers cross-resistance to other CDK inhibitors but not to chemotherapeutic agents in breast cancer cells.
Ogata R; Kishino E; Saitoh W; Koike Y; Kurebayashi J
Breast Cancer; 2021 Jan; 28(1):206-215. PubMed ID: 32860163
[TBL] [Abstract][Full Text] [Related]
9. Targeting PEG10 as a novel therapeutic approach to overcome CDK4/6 inhibitor resistance in breast cancer.
Katuwal NB; Kang MS; Ghosh M; Hong SD; Jeong YG; Park SM; Kim SG; Sohn J; Kim TH; Moon YW
J Exp Clin Cancer Res; 2023 Nov; 42(1):325. PubMed ID: 38017459
[TBL] [Abstract][Full Text] [Related]
10. Cyclin-Dependent Kinase 4/6 Inhibitors Beyond Progression in Metastatic Breast Cancer: A Retrospective Real-World Biomarker Analysis.
Gerratana L; Davis AA; Velimirovic M; Reduzzi C; Clifton K; Bucheit L; Hensing WL; Shah AN; Pivetta T; Dai CS; D'Amico P; Wehbe F; Medford A; Wander SA; Gradishar WJ; Behdad A; Ma CX; Puglisi F; Bardia A; Cristofanilli M
JCO Precis Oncol; 2023 May; 7():e2200531. PubMed ID: 37141549
[TBL] [Abstract][Full Text] [Related]
11. Clinical management of metastatic hormone receptor-positive, HER2-negative breast cancer (MBC) after CDK 4/6 inhibitors: a retrospective single-institution study.
Choong GM; Liddell S; Ferre RAL; O'Sullivan CC; Ruddy KJ; Haddad TC; Hobday TJ; Peethambaram PP; Liu MC; Goetz MP; Giridhar KV
Breast Cancer Res Treat; 2022 Nov; 196(1):229-237. PubMed ID: 36045271
[TBL] [Abstract][Full Text] [Related]
12. Dendritic cell therapy augments antitumor immunity triggered by CDK4/6 inhibition and immune checkpoint blockade by unleashing systemic CD4 T-cell responses.
Kumar A; Ramani V; Bharti V; de Lima Bellan D; Saleh N; Uzhachenko R; Shen C; Arteaga C; Richmond A; Reddy SM; Vilgelm A
J Immunother Cancer; 2023 May; 11(5):. PubMed ID: 37230537
[TBL] [Abstract][Full Text] [Related]
13. CD63
Sun J; Du R; Li X; Liu C; Wang D; He X; Li G; Zhang K; Wang S; Hao Q; Zhang Y; Li M; Gao Y; Zhang C
Cancer Lett; 2024 Apr; 588():216747. PubMed ID: 38403110
[TBL] [Abstract][Full Text] [Related]
14. Co-targeting RANK pathway treats and prevents acquired resistance to CDK4/6 inhibitors in luminal breast cancer.
Gomes I; Gallego-Paez LM; Jiménez M; Santamaria PG; Mansinho A; Sousa R; Abreu C; Suárez EG; Costa L; Casimiro S
Cell Rep Med; 2023 Aug; 4(8):101120. PubMed ID: 37451269
[TBL] [Abstract][Full Text] [Related]
15. The Genomic Landscape of Intrinsic and Acquired Resistance to Cyclin-Dependent Kinase 4/6 Inhibitors in Patients with Hormone Receptor-Positive Metastatic Breast Cancer.
Wander SA; Cohen O; Gong X; Johnson GN; Buendia-Buendia JE; Lloyd MR; Kim D; Luo F; Mao P; Helvie K; Kowalski KJ; Nayar U; Waks AG; Parsons SH; Martinez R; Litchfield LM; Ye XS; Yu C; Jansen VM; Stille JR; Smith PS; Oakley GJ; Chu QS; Batist G; Hughes ME; Kremer JD; Garraway LA; Winer EP; Tolaney SM; Lin NU; Buchanan SG; Wagle N
Cancer Discov; 2020 Aug; 10(8):1174-1193. PubMed ID: 32404308
[TBL] [Abstract][Full Text] [Related]
16. Detection of high-risk patients resistant to CDK4/6 inhibitors with hormone receptor-positive HER2-negative advanced and metastatic breast cancer in Japan (KBCSG-TR-1316).
Futamura M; Nakayama T; Yoshinami T; Oshiro C; Ishihara M; Morita M; Watanabe A; Tanigichi A; Tsukabe M; Shimoda M; Nitta K; Chihara Y; Yasojima H; Ouchi Y; Tokumaru Y; Masuda N
Breast Cancer; 2023 Nov; 30(6):943-951. PubMed ID: 37486454
[TBL] [Abstract][Full Text] [Related]
17. Activation of the IFN Signaling Pathway is Associated with Resistance to CDK4/6 Inhibitors and Immune Checkpoint Activation in ER-Positive Breast Cancer.
De Angelis C; Fu X; Cataldo ML; Nardone A; Pereira R; Veeraraghavan J; Nanda S; Qin L; Sethunath V; Wang T; Hilsenbeck SG; Benelli M; Migliaccio I; Guarducci C; Malorni L; Litchfield LM; Liu J; Donaldson J; Selenica P; Brown DN; Weigelt B; Reis-Filho JS; Park BH; Hurvitz SA; Slamon DJ; Rimawi MF; Jansen VM; Jeselsohn R; Osborne CK; Schiff R
Clin Cancer Res; 2021 Sep; 27(17):4870-4882. PubMed ID: 33536276
[TBL] [Abstract][Full Text] [Related]
18. Inhibition of CK1ε potentiates the therapeutic efficacy of CDK4/6 inhibitor in breast cancer.
Dang F; Nie L; Zhou J; Shimizu K; Chu C; Wu Z; Fassl A; Ke S; Wang Y; Zhang J; Zhang T; Tu Z; Inuzuka H; Sicinski P; Bass AJ; Wei W
Nat Commun; 2021 Sep; 12(1):5386. PubMed ID: 34508104
[TBL] [Abstract][Full Text] [Related]
19. Safety and feasibility of CDK4/6 inhibitors treatment combined with radiotherapy in patients with HR-positive/HER2-negative breast cancer. A systematic review and meta-analysis.
Kubeczko M; Jarząb M; Gabryś D; Krzywon A; Cortez AJ; Xu AJ
Radiother Oncol; 2023 Oct; 187():109839. PubMed ID: 37536378
[TBL] [Abstract][Full Text] [Related]
20. Combination of ZEN-3694 with CDK4/6 inhibitors reverses acquired resistance to CDK4/6 inhibitors in ER-positive breast cancer.
Kharenko OA; Patel RG; Calosing C; van der Horst EH
Cancer Gene Ther; 2022 Jun; 29(6):859-869. PubMed ID: 34385584
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
